close
MENU
Hot Topic Hawke’s Bay
Hot Topic Hawke’s Bay
Investment
3 mins to read

US blow to major sleep device maker not a boon to F&P: analyst

Sleep devices made by Philips Respironics pulled from the market in the US, but the move may hold back other market players including F&P.

The Philips DreamStation 2 CPAP machine for home-based treatment of sleep apnoea.

Dita De Boni Wed, 31 Jan 2024

News that global breathing machine manufacturer Philips has been forced to stop selling its sleep apnoea devices in the US after the industrial foam used in the machines was found to be unsafe is not expected to hand a huge victory to New Zealand’s Fisher & Paykel Healthcare, a local analyst has

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Dita De Boni Wed, 31 Jan 2024
Contact the Writer: dita@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
US blow to major sleep device maker not a boon to F&P: analyst
Investment,
102506
true